Long - Acting Formulations Of Insulins

Abstract

The application relates to an aqueous pharmaceutical formulation comprising 200 – 1000 U/mL [equimolar to 200 –1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine, and its use.

Fig. 3